Pharmaceutical

Radiopharm and AtomVie partner on radioantibody development

Radiopharm Theranostics (RAD) and AtomVie have announced a partnership for the development and manufacturing of 177Lu-BetaBart.

Oct 18, 2024 - 04:00
Radiopharm and AtomVie partner on radioantibody development
Radiopharm Theranostics (RAD) and AtomVie have announced a partnership for the development and manufacturing of 177Lu-BetaBart.
Read the original article

Tags:

Previous Article

bit.bio defends European patent for ‘novel’ opti-ox technology

Next Article

Intercept’s liver disease drug Ocaliva faces FDA approval delay

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Pharmalittle: Weight loss drugs cost much more in the U.S.; PBMs win a key victory over an Oklahoma law

STAT+: Pharmalittle: Weight loss drugs cost much more i...

Aug 19, 2023

Ginkgo Bioworks partners with WARF for new GD2 CAR T-cell therapies

Ginkgo Bioworks partners with WARF for new GD2 CAR T-ce...

Apr 14, 2023

STAT+: Congress punts on PBM reform efforts

STAT+: Congress punts on PBM reform efforts

Feb 27, 2024